PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
21-Apr-2020 NTC Grants License and Distribution Rights in Mexico to Laboratorios Grin S.A. de C.V, for Its Fixed Combination of an Ophthalmic Quinolone Antibiotic With an Anti-inflammatory Steroid NTC Srl
21-Apr-2020 Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder Harbour BioMed
21-Apr-2020 Hardman & Co Research: Q&A with Mark Thomas on Arbuthnot Banking Group (ARBB): 2019 results - resilience into the storm Hardman & Co Research
21-Apr-2020 4SC provides Q1 2020 update 4SC AG
21-Apr-2020 Pharming Reports Encouraging Results From Use of RUCONEST® in COVID-19 Patients Pharming Group N.V.
21-Apr-2020 Sartorius Off to a Dynamic Start in Fiscal 2020 Sartorius AG
21-Apr-2020 Sartorius Stedim Biotech With a Strong Start in 2020 Sartorius Stedim Biotech S.A.
20-Apr-2020 Correction of a release from 20/04/2020, 22:53 CET/CEST - Drägerwerk AG & Co. KGaA: Dräger sets placement price of new preference shares and raises EUR 76.5 million in gross proceeds and terminates series A and K participation certificates Drägerwerk AG & Co. KGaA
20-Apr-2020 Drägerwerk AG & Co. KGaA: Dräger sets placement price of new preference shares and raises EUR 76.5 million in gross proceeds and terminates series A and K participation certificates Drägerwerk AG & Co. KGaA
20-Apr-2020 4basebio AG: 4basebio AG resolves on capital reduction by way of redemption of approx. 5.2 million treasury shares in accordance with the authorizing resolution of the general meeting 4basebio AG
20-Apr-2020 4D pharma announces expedited UK regulatory acceptance to commence Phase II study in COVID-19 4D pharma
20-Apr-2020 HumanOptics AG: Dr. Pierre Billardon leaves the Management Board on 30 April 2020; Diana Bachmann appointed as his successor HumanOptics AG
20-Apr-2020 Drägerwerk AG & Co. KGaA: Dräger resolves capital increase of preferred shares (ISIN: DE0005550636) against cash contributions from authorized capital Drägerwerk AG & Co. KGaA
20-Apr-2020 Biofrontera AG: Biofrontera Reports Full Year 2019 Financial Results Biofrontera AG
20-Apr-2020 Transcenta Received IND Clearance from FDA for Initiating Clinical Trials for its Novel Humanized Claudin 18.2 Monoclonal Antibody TST001 Transcenta
20-Apr-2020 Solentim and ATUM to bundle Leap-In Transposase® with the VIPS™ single cell cloning instrument for cell line development Sciad Newswire
20-Apr-2020 Registration Opens for SMi's Inaugural Aseptic Processing Conference SMi Group
20-Apr-2020 Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse(TM) Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors Precigen, Inc.
20-Apr-2020 COVID-19 Update: Highly Potent Active Pharmaceutical Ingredients 2020 now Remote Access only SMi Group
20-Apr-2020 Biofrontera AG: Biofrontera AG enters into exclusive license agreement with Maruho Co., Ltd. Biofrontera AG